Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Zogenix, Inc.    ZGNX

ZOGENIX, INC. (ZGNX)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
OFFRE
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/13/2018 09/14/2018 09/17/2018 09/18/2018 09/19/2018 Date
48.75(c) 48.8(c) 48.5(c) 48.65(c) 47.05(c) Last
482 919 374 300 544 408 381 805 566 123 Volume
+1.04% +0.10% -0.61% +0.31% -3.29% Change
More quotes
Financials (USD)
Sales 2018 -
EBIT 2018 -143 M
Net income 2018 -135 M
Finance 2018 518 M
Yield 2018 -
Sales 2019 29,1 M
EBIT 2019 -129 M
Net income 2019 -121 M
Finance 2019 361 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 0
EV / Sales2019 55,1x
Capitalization 1 968 M
More Financials
Company
Zogenix, Inc. is a pharmaceutical compan.It engages in the development and commercialization of central nervous system (CNS) therapies and products for the treatment orphan diseases and other CNS disorders.Its products include ZX008 and Relday.The company was founded by Stephen J. Farr, Cam L.... 
More about the company
Surperformance© ratings of Zogenix, Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on ZOGENIX, INC.
09/07ZOGENIX : Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(4..
AQ
09/06ZOGENIX : Phase 2 Study Results Published in Epilepsia Show ZX008 Provides Durab..
AQ
09/05ZOGENIX : Phase 2 Study Results Published in Epilepsia Show ZX008 Provides Durab..
AQ
09/05ZOGENIX : Phase 2 Study Results Published in Epilepsia Show ZX008 Provides Durab..
AQ
09/04ZOGENIX : Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c..
AQ
09/04ZOGENIX : The Global Needle-Free Delivery Technology Market Will Reach $2,093.9m..
AQ
09/04TODAY'S RESEARCH REPORTS ON TRENDING : CRISPR Therapeutics and Zogenix
AC
09/04Zogenix Phase 2 Study Results Published in Epilepsia Show ZX008 Provides Dura..
GL
08/31ZOGENIX : Announces New Data on Psychological and Socioeconomic Impact of Dravet..
AQ
08/30ZOGENIX : Announces New Data on Psychological and Socioeconomic Impact of Dravet..
AQ
More news
Sector news : Bio Medical Devices
09/19NOVARTIS : U.K. Pulls Brakes on Novartis' CAR-T Drug in First European Setback -..
DJ
09/19NOVARTIS : U.K. Pulls Brakes on Novartis' CAR-T Drug for Some Patients Despite D..
DJ
09/19GILEAD SCIENCES : UK rejects adult Novartis CAR-T therapy, after 'yes' in kids
RE
09/18REGENERON PHARMACEUTICALS : Sanofi pledges to keep up its restructuring efforts
RE
09/14Allogene, Which Announced Pfizer Agreement in April, Discloses IPO Plans
DJ
More sector news : Bio Medical Devices
Latest Tweets
09/19Have you seen Lee Michael Smith? He's gone missing from Harehills and police ..
19
09/19The one of a kind home was designed by Michael Smith.
3
09/17$ZGNX looking to work out of a nice base here 
09/16Zogenix $ZGNX Research Coverage Started at Northland Securities  
09/14Next few weeks of guests scheduled on "Behind the Mic with Greg Wrubell" (Wed..
1
More tweets
Qtime:186
News from SeekingAlpha
09/14Premarket analyst action - healthcare 
09/07YOUR DAILY SCOOP : Recro Proceeds, MannKind Zooms, Aduro's Publication 
09/07Premarket analyst action - healthcare 
09/04Zogenix's ZX008 shows positive effect in mid-stage study in rare childhood ep.. 
08/23FDA OKs new treatment for Dravet syndrome 
Chart ZOGENIX, INC.
Duration : Period :
Zogenix, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ZOGENIX, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 12
Average target price 78,6 $
Spread / Average Target 67%
EPS Revisions
Managers
NameTitle
Stephen J. Farr President, Chief Executive Officer & Director
Cam L. Garner Chairman
Michael Patrick Smith CFO, Secretary, Treasurer & Executive VP
Bradley S. Galer Chief Medical Officer & Executive Vice President
Roger L. Hawley Director
Sector and Competitors
1st jan.Capitalization (M$)
ZOGENIX, INC.17.48%1 968
GILEAD SCIENCES3.13%94 348
VERTEX PHARMACEUTICALS18.19%44 927
REGENERON PHARMACEUTICALS3.29%41 024
CELLTRION, INC.--.--%33 722
IQVIA HOLDINGS INC27.92%25 338